Report summary
• Presentation for investigation and/or treatment of gastrointestinal (GI) disease comprised 3.0 per cent, 2.0 per cent and 1.9 per cent of total dog, cat and rabbit consultations respectively between 1 April 2017 and 31 October 2018
• Diarrhoea and vomiting without blood were the most frequently reported GI disease clinical signs (43.0 and 36.6 per cent in dogs, and 35.9 and 37.7 per cent in cats respectively)
• The proportion of GI disease consultations which prescribed antibiotics authorised for systemic administration (including oral and injectable formulations) decreased between April 2014 and October 2018
• The proportion of GI disease consultations which dispensed nutraceutical products advertised as being effective at managing primary GI disease (including prebiotics, probiotics etc.) increased between April 2014 and October 2018 
About this report
This report is the seventh in a series by the Small Animal Veterinary Surveillance Network (SAVSNET). The other reports in the series are available from http://veterinaryrecord.bmj.com.
As data are collected for longer periods, the estimates of changes in disease burden will become more refined, allowing more targeted local and perhaps national interventions. Anonymised data can be accessed for research by contacting the authors. SAVSNET also welcomes feedback on this report. More information about SAVSNET is available at www.liverpool.ac.uk/savsnet
Syndromic surveillance of GI disease
This report represents the third occasion the Small Animal Veterinary Surveillance Network (SAVSNET) has summarised GI disease in companion animals (Arsevska and others 2017; Sánchez-Vizcaíno and others 2015) . The present report considers electronic health records consultations were analysed, of which 69.8 per cent were from dogs, 26.8 per cent were from cats, 1.7 per cent were from rabbits, and the remaining 1.6 per cent were from other species, or where species was not recorded. Animals mainly presenting for investigation and/or treatment of GI disease according to the attending veterinary surgeon or nurse comprised 3.0 per cent, 2.0 per cent and 1.9 per cent of total dog, cat and rabbit consultations respectively.
Short questionnaires (Sánchez-Vizcaíno and others 2015) were completed by the attending practitioner after 13,768 random GI disease consultations (10,682 canine, 2,767 feline and including 13,098 unique animals). Most animals presented with mild GI clinical signs (82.1 per cent of dogs, 78.7 per cent of cats) after a history of illness of up to two days (51.8 per cent of dogs, 38.7 per cent of cats), where the surveyed consultation represented the first occasion the animal had presented to the veterinary professional for this episode of GI disease (70.3 per cent of dogs, 61.7 per cent of cats). The most common presenting signs in both species were diarrhoea and/or vomiting, in both cases without blood (Table 1) .
Haematological/biochemical analyses were the most common diagnostic tests performed (8.3 per cent of dogs, 12.7 per cent of cats), followed by parasitological or bacteriological analyses on faeces (7.8 per cent of dogs, 6.8 per cent of cats). A change of diet was the most commonly provided advice, being recommended in 56.9 per cent of dogs and 45.8 per cent of cats. These findings were broadly consistent with SAVSNET's previous reviews of GI disease (Arsevska and others 2017; Sánchez-Vizcaíno and others 2015) .
Spatial distribution of gastrointestinal disease
The spatial distribution of the relative risk for GI disease was evaluated in dogs and cats in England, Scotland and Wales for each season of the surveillance period between 1 October postcode was used to indicate the likely residence of each recorded animal. Hence, these centroids were aggregated into 20km gridded cells encompassing England, Scotland and Wales, calculating the proportion of total consultations which included an animal mainly presenting for GI disease. Standard error (SE) for each cell was also calculated to provide a measure of relative confidence in findings due to variable geographic consultation coverage, with these values being used to formulate septile bi-variate maps, where the darkest red colours indicate highest proportions of GI disease (greater than 5.6 per cent and 3.7 per cent for dogs and cats respectively) (compared to median incidence) and lowest standard errors (Fig.1) .
As previously noted in both dogs and cats (Sánchez-Vizcaíno and others 2015), we observed transient regions of increased GI disease incidence distributed fairly randomly throughout the country and in most seasons, as indicated by the darkest red areas in figure 1. These were most numerous for dogs. It is anticipated in future that SAVSNET will conduct more in-depth analyses of these transient increased incidence regions to ascertain presence or absence of a GI disease outbreak.
Gastrointestinal disease pharmacosurveillance
For the first time in this report we also analysed pharmaceutical product prescriptions given during all GI consultations recorded between April 1 2014 and October 31 2018 in dogs (n = 124,159 GI consultations), cats (n = 32,902) and rabbits (n = 2,123). A semi-automated text mining methodology was utilised to identify the active substance(s) dispensed in each consultation using the 'product dispensed' field of the EHR; these active substances were hence summarised into a hierarchical pharmaceutical classification system as previously described (Singleton and others 2018; Singleton and others 2017) . For the purposes of this report, five pharmaceutical families of particular relevance to GI disease were analysed, including antibiotics authorised for systemic (oral or injectable) use; anti-inflammatories authorised for systemic use; any endoparasiticide or endectocide; gastrointestinally-active (GI-A) products (e.g. proton pump inhibitors), and euthanasia. Nutraceuticals advertised as being effective at treating primary GI disease including prebiotics, probiotics, kaolin etc. were also analysed.
For dogs, GI pharmaceutical products were prescribed in 37.5 per cent of GI consultations, systemic antibiotics in 36.9 per cent, systemic anti-inflammatories in 11.1 per cent, and endoparasiticides / endectocides in 6.9 per cent. For cats, GI-A products were prescribed in 29.2 per cent of GI consultations, systemic antibiotics in 25.7 per cent, systemic anti-inflammatories in 18.3 per cent, and endoparasiticides / endectocides in 11.9 per cent. For rabbits, GI-A products were prescribed in 55.6 per cent of GI consultations, systemic antibiotics in 13.9 per cent, systemic anti-inflammatories in 39.1 per cent, and endoparasiticides / endectocides in 3.2 per cent. GI nutraceuticals were dispensed in 35.4 per cent of dog GI consultations, 17.3 per cent of cat, and 10.6 per cent of rabbit GI consultations. Dogs were euthanised in 0.2 per cent of GI consultations, compared to 0.7 per cent of cat and 1.4 per cent of rabbit GI consultations.
Temporal trends in prescription and dispensing frequency were also examined in dogs and cats (Fig.2) . Over the 4.5 years analysed a decrease in the frequency with which systemic antibiotics and systemic anti-inflammatories were prescribed was noted in this population, with the opposite trend being noted for GI-A pharmaceutical products and GI nutraceuticals. No clear temporal variation in euthanasia frequency was seen in either species.
Laboratory-based investigations of Tritrichomonas foetus infection in companion animals
SAVSNET collated data from four participating UK-based veterinary diagnostic laboratories Due to a low number of canine tests, temporal and spatial trends were examined for cats alone.
Over the eight years analysed, we observed a relatively steady decline in the proportion of feline tests returning a positive T.foetus result (Fig.3) . Whether this represents a true decrease in T.foetus prevalence, or a changing approach to diagnosis of this parasite in practice and/or VDLs remains to be determined. Considered in total, a greater proportion of tests conducted in winter returned a positive result (15.2 per cent of tests), followed by spring (14.1 per cent), autumn (13.2 per cent), and summer (11.7 per cent). Regarding spatial trends, collating all tests completed between 2011 and 2018, though varied coverage should be considered, both areas of relatively high and low positive test proportions were revealed in postcode areas for which we hold relatively high volumes of data (equating to low standard error), suggesting variable T.foetus infection risk in different regions of the country (Fig.4) . Though to our knowledge it has been some years since T.foetus infection in cats has been surveyed in the UK our findings are broadly similar to a 2007 study (Gunn-Moore and others 2007).
Update on main presenting complaint temporal trends in companion animals
An observed prevalence time series for three key main presenting complaints (pruritus, These results show continued seasonal prevalence fluctuations in both species, particularly apparent for pruritus in both dogs and cats, and respiratory disease in dogs. In dogs, this seasonal pattern for pruritus appeared extremely stable, with no evidence of moderate or extreme perturbations in recent expected levels of disease. Other syndromes were less stable, suggesting an extreme increase in gastroenteritis cases above expected levels for cats around August 2018, and for respiratory disease in dogs (summer 2018). It is currently unknown whether these findings represent a true increase in disease prevalence, or reflect the changing nature of participation in the SAVSNET project.
Global perspective

Campylobacter jejuni in dogs in the USA
In our last surveillance report we reported on an outbreak of Campylobacter affecting both puppies in a national pet store chain and 118 people in 18 states of the USA, leading to the hospitalisation of 26 people. Tested isolates were considered resistant to many classes of antibiotic, the use of which in puppies was widespread in the pet store, often for prophylactic reasons. Further analysis has now identified the species involved as C.jejuni (Montgomery and 
Imported rabies
The sad news of the recent death of a man in the UK of rabies, contracted from a cat bite in Morocco, reminds us both of the dangers still posed by this lethal virus, and that although most human cases are associated with dog bites, cats and other animals can also transmit the virus to people. This is the sixth such case of rabies in the UK associated with exposure abroad since 
Imported monkeypox
Travel was also at the heart of a recent mini-outbreak of monkeypox in England this September affecting three people, two of which had recently travelled from Nigeria where they are believed to have acquired the infection independent of each other; the third case was a healthcare worker caring for one of the cases (PHE 2018) . Monkeypox is a rare zoonosis related to smallpox (which itself has been eradicated globally) and cowpox. Although most infections are mild and most people recover, it can be fatal especially in young children and the immunosuppressed.
Update on Tritrichomonas foetus in cats The organism
Tritrichomonas foetus is a single-celled protozoan parasite that can infect the distal ileum, caecum and colon of cats resulting in predominantly large intestinal diarrhoea. In cattle, T.foetus can infect the reproductive tract leading to reproductive disease (including endometritis, infertility and abortion), whilst in pigs it colonises the nasal cavity and GI tract. It is unclear whether isolates from different host species represent separate species. This agent is rarely zoonotic, but good hygiene practice should be applied when handling infected cats or their waste products particularly by immunosuppressed individuals.
Transmission is via the faeco-oral route, with organisms remaining viable in moist faeces for a small number of days. Young cats (<1year age) most commonly show clinical signs, although any age can be affected. Prevalence in cats with diarrhoea is variable, with younger cats and those from multi-cat households (especially breeding colonies) at increased risk.
Clinical signs
Most cats are presented with a chronic history of waxing and waning, malodourous, large intestinal diarrhoea with variably increased frequency, increased mucus, haematochezia, tenesmus, and flatulence. In some cats this can progress into faecal incontinence, perianal swelling and dermatitis. Cats are often otherwise well in themselves.
Diagnosis
Diagnosis is based on either direct microscopic visualisation of organisms (wet mount preparation), faecal culture (using the 'InPouch' system), or detection of organism DNA in faeces (whole or via colonic wash) by PCR. Microscopically, T. foetus has a similar size and shape to Giardia spp.; however, T.foetus has a rapid, jerking movement (c.f. slow, falling-leaf movement of Giardia spp.). Co-infections with Giardia spp. are possible. PCR is most sensitive, and is the recommended method of detection.
False negative results can occur, particularly when whole faeces are submitted for testing or if there is a delay in testing (for direct visualisation and culture). As the colonic mucus is the site of infection, obtaining a sample of this increases the sensitivity of detection in infected cats.
Mucus may be collected from faecal motions, passed as part of the clinical disease process; a faecal loop may be used to obtain a sample of faeces and mucus directly from the colon; or (preferably) a colonic wash is performed (description and images available in Gookin and others 2017).
Treatment
Although clinical signs may improve on antibiotics, this is attributed to indirect effects on reducing Trichomonas numbers, and diarrhoea typically recurs shortly following discontinuation. Feeding of bland or high-fibre diets have also been suggested to be beneficial, again possibly via indirect effects; however, there are little data to support this. Clinical signs can resolve without treatment but affected cats likely remain a reservoir of infection.
The only agent with proven efficacy against T. foetus is ronidazole, which is effective in around two thirds of cases (Xenoulis and others 2013) . Current recommended doses are 20-30 mg/kg orally once daily for 14 days and should be based on accurate weight measurement (GruffyddJones and others 2013). Doses in young kittens (not 12 weeks age) or cats with hepatic dysfunction should be reduced to 10 mg/kg to minimise risk of adverse effects. As it is teratogenic, ronidazole should not be administered to pregnant or nursing queens (NB: owners should wear gloves when administering). Administration of a probiotic (eg Pro-Kolin Enterogenic, Protexin) for four weeks is also recommended. Metronidazole should not be given concurrently due to increased risk of toxicity.
Adverse effects of ronidazole are primarily related to neurotoxicity (lethargy, inappetence, ataxia, tremors, and seizures) with vomiting less frequent. If adverse effects were to manifest, the ronidazole should be immediately discontinued. Obtaining informed, written, owner consent prior to treatment is strongly recommended.
Ronidazole is not currently available as a licensed product for use in cats. Currently, only two UK compounding pharmacies supply reformulated capsules or liquid direct to veterinary practices -Nova Laboratories (www.novalabs.co.uk) and Summit Veterinary Pharmaceuticals (www.svprx.co.uk).
Control
Treatment failures are possible, and potentially due to inappropriate dosage of medication, poor compliance, re-infection or resistance to ronidazole. To reduce the risk of re-infection and transmission, good hygiene practice should be in place, in particular the frequent emptying and cleaning of cat litter trays. If possible, infected cats should be isolated.
Treatment of all cats within a cattery in which a T. foetus-infected cat has been documented but is controversial due to risk of adverse effects, alongside the potential for treatment failure leading to re-infection. Q2 2014 -Q4 2018) . Also described are the percentage of GI consultations where a GI nutraceutical was dispensed, or the animal was euthanised. Shaded regions refer to 95% confidence intervals, calculated to adjust for clustering within veterinary practice site (bootstrapped estimated, n replicates = 5,000). 
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